WO1999019327A1 - Process for the synthesis of chloropurine intermediates - Google Patents
Process for the synthesis of chloropurine intermediates Download PDFInfo
- Publication number
- WO1999019327A1 WO1999019327A1 PCT/GB1998/003080 GB9803080W WO9919327A1 WO 1999019327 A1 WO1999019327 A1 WO 1999019327A1 GB 9803080 W GB9803080 W GB 9803080W WO 9919327 A1 WO9919327 A1 WO 9919327A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- acid
- compound
- ims
- carried out
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 29
- 239000000543 intermediate Substances 0.000 title description 10
- 230000015572 biosynthetic process Effects 0.000 title description 3
- 238000003786 synthesis reaction Methods 0.000 title description 3
- JBMBVWROWJGFMG-UHFFFAOYSA-N 2-chloro-7h-purine Chemical compound ClC1=NC=C2NC=NC2=N1 JBMBVWROWJGFMG-UHFFFAOYSA-N 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 34
- 239000002253 acid Substances 0.000 claims abstract description 13
- 238000011065 in-situ storage Methods 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- 150000003839 salts Chemical class 0.000 claims abstract description 6
- 125000006239 protecting group Chemical group 0.000 claims abstract description 5
- 230000003301 hydrolyzing effect Effects 0.000 claims abstract description 3
- 238000006798 ring closing metathesis reaction Methods 0.000 claims abstract description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 24
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 10
- 238000010992 reflux Methods 0.000 claims description 10
- 230000007062 hydrolysis Effects 0.000 claims description 9
- 238000006460 hydrolysis reaction Methods 0.000 claims description 9
- 239000002585 base Substances 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 6
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 125000002252 acyl group Chemical group 0.000 claims description 5
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 claims description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 5
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 4
- 239000011707 mineral Substances 0.000 claims description 4
- 235000010755 mineral Nutrition 0.000 claims description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 4
- 239000003125 aqueous solvent Substances 0.000 claims description 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 3
- 239000002798 polar solvent Substances 0.000 claims description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 3
- 238000007363 ring formation reaction Methods 0.000 claims description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical group [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 229910000288 alkali metal carbonate Inorganic materials 0.000 claims description 2
- 150000008041 alkali metal carbonates Chemical class 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 claims description 2
- 239000008139 complexing agent Substances 0.000 claims description 2
- 238000006482 condensation reaction Methods 0.000 claims description 2
- 150000004292 cyclic ethers Chemical class 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 125000005270 trialkylamine group Chemical group 0.000 claims description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 4
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 claims 1
- 125000003158 alcohol group Chemical group 0.000 claims 1
- QWTDNUCVQCZILF-UHFFFAOYSA-N iso-pentane Natural products CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 claims 1
- -1 carbocyclic purine nucleoside analogue Chemical class 0.000 abstract description 6
- 239000007787 solid Substances 0.000 description 14
- 239000000203 mixture Substances 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 239000000725 suspension Substances 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 229960004748 abacavir Drugs 0.000 description 5
- 239000011928 denatured alcohol Substances 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 239000002002 slurry Substances 0.000 description 4
- 0 *[C@]1C=C[C@](CO)C1 Chemical compound *[C@]1C=C[C@](CO)C1 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- XYWHZUCZNRMJGO-UHFFFAOYSA-N n-(2-amino-4,6-dichloropyrimidin-5-yl)formamide Chemical compound NC1=NC(Cl)=C(NC=O)C(Cl)=N1 XYWHZUCZNRMJGO-UHFFFAOYSA-N 0.000 description 3
- MWBWWFOAEOYUST-UHFFFAOYSA-N 2-aminopurine Chemical compound NC1=NC=C2N=CNC2=N1 MWBWWFOAEOYUST-UHFFFAOYSA-N 0.000 description 2
- 150000005019 2-aminopurines Chemical class 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- HWSJQFCTYLBBOF-UHFFFAOYSA-N 2,5-diamino-4-hydroxy-1h-pyrimidin-6-one Chemical compound NC1=NC(O)=C(N)C(O)=N1 HWSJQFCTYLBBOF-UHFFFAOYSA-N 0.000 description 1
- ZXWGHENZKVQKPX-UHFFFAOYSA-N 4,6-dichloropyrimidine-2,5-diamine Chemical compound NC1=NC(Cl)=C(N)C(Cl)=N1 ZXWGHENZKVQKPX-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- 241001480079 Corymbia calophylla Species 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 235000006552 Liquidambar styraciflua Nutrition 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- IHEDZPMXLKYPSA-RQJHMYQMSA-N Nc1nc(Cl)c2nc[n]([C@H]3C=C[C@@H](CO)C3)c2n1 Chemical compound Nc1nc(Cl)c2nc[n]([C@H]3C=C[C@@H](CO)C3)c2n1 IHEDZPMXLKYPSA-RQJHMYQMSA-N 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 150000001414 amino alcohols Chemical class 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- QQVDYSUDFZZPSU-UHFFFAOYSA-M chloromethylidene(dimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)=CCl QQVDYSUDFZZPSU-UHFFFAOYSA-M 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 150000001941 cyclopentenes Chemical class 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000003948 formamides Chemical class 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229940126532 prescription medicine Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the present invention relates to a process for the preparation of a carbocyclic purine nucleoside analogue of formula (I) , its salts and pharmaceutically acceptable derivatives thereof.
- EP 0434450 This is described in EP 0434450 as having potent activity against human immunodeficiency virus (HIV) and hepatitis B virus (HBV) .
- the protecting group P will desirably be an acyl or substituted oxycarbonyl group.
- One aspect of the present invention comprises an in situ conversion of cyclopentenes of formula (IV) to 2- aminopurine derivatives of formula (I) easily and conveniently without the need to isolate any intermediates.
- the deprotection of the starting material of formula (IV) in situ provides the desired amino alcohol without any wasteful workup, and because of the direct coupling and cyclisation, again without any work up or isolation of intermediates, the overall yield of the process is increased.
- preferred protecting groups in the compound of formula (IV) are acyl or substituted oxycarbonyl groups .
- Preferred acyl groups include for yl or lower alkanoyl (having e.g. 1 to 4 carbon atoms in the alkyl portion) , especially an acetyl group .
- Preferred substituted oxycarbonyl groups will be of the formula R'OC(O)-, wherein R' may be an alkyl or aralkyl group.
- a preferred alkyl group is tert butyl; a preferred aralkyl group is benzyl.
- the hydrolysis step is preferably achieved by mild acid- catalysed hydrolysis in an organic solvent, such as an alkanol, a cyclic ether or a chlorinated hydrocarbon. It is preferred to use an organic or mineral acid such as trifluoroacetic acid or hydrochloric acid in an alkanol solvent such as industrial methylated spirit (IMS) , optionally in the presence of water.
- organic solvent such as an alkanol, a cyclic ether or a chlorinated hydrocarbon.
- an organic or mineral acid such as trifluoroacetic acid or hydrochloric acid
- an alkanol solvent such as industrial methylated spirit (IMS)
- the condensation step is then carried out without any isolation of the hydrolysis product of formula (V) .
- This condensation reaction is preferably carried out under reflux in a polar solvent such as an alcohol, e.g. ethanol or butanol, or water or acetonitrile, or mixtures thereof, in the presence of at least sufficient base to neutralise both the acid used for the hydrolysis and that produced during the condensation.
- a polar solvent such as an alcohol, e.g. ethanol or butanol, or water or acetonitrile, or mixtures thereof.
- the base will desirably be a trialkylamine or an alkali metal carbonate or bicarbonate, e.g. potassium or sodium carbonate, and more preferably, sodium bicarbonate.
- Preferred combinations are triethylamine or sodium bicarbonate in IMS.
- the group R in the compound of formula (VI) preferably represents CHO.
- the ring closure reaction is then carried out, again without any isolation of any preceding intermediate product of formula (VII) .
- This is conveniently carried out using trialkylorthoformates in the presence of concentrated aqueous or anhydrous mineral acid, optionally in the presence of one or more non-aqueous solvents, e.g. tetrahydrofuran, ethyl acetate or IMS.
- the unisolated product of formula (VII) is added to a mixture of acid and a trialkylorthoformate .
- a preferred combination comprises use of from about 1.5 to 3, preferably around 2 molar equivalents of hydrochloric acid in triethylorthoformate, which results in precipitation of the hydrochloride salt of the 9- substituted-2-amino purine of formula (I) .
- the free base may, if desired, be liberated by treatment with base .
- the process of the invention has been found to provide yields of compounds of formula (I) starting from a compound of formula (IV) of in excess of 80%. This compares very favourably with yields of compounds of formula (I) which are obtained using earlier stepwise procedures in which the intermediates are isolated, which give, typically around 56% when the compound of formula (III) is used as starting material, or yields of around 75% when the procedure described in Publication No. W095/21161 is used, starting from a compound of formula (V) .
- the compounds of formula (VI) can be synthesised by a method as described in W095/21161.
- the compound can be synthesised from the readily available 2 , 5-diamino-4 , 6- dihydroxypyrimidine , by reacting this with a Vilsmeier reagent of formula (VIII)
- R x and R 2 are as defined in W095/21161, viz: that R x and R 2 , which may be the same or different are selected from C ⁇ . _ 8 straight- chain alkyl, C ⁇ g branched alkyl, C 3 _ 8 cycloalkyl, and aryl groups (such as phenyl or naphthyl) , which may be optionally substituted, for example by C ⁇ _ 4 alkyl or halogen (e.g. Cl) .
- R x and R 2 are both methyl) , followed by hydrolysis.
- Compounds of formula (VIII) may be prepared from a variety of formamides of secondary amines by reaction with a variety of acid halides, such as phosphorus oxychloride, phosphorus pentachloride, thionyl chloride, phosgene, and oxalyl chloride, for example as detailed in a review by CM. Marson, Tetrahedon 1992, 48:3660- 3720 and references therein.
- acid halides such as phosphorus oxychloride, phosphorus pentachloride, thionyl chloride, phosgene, and oxalyl chloride, for example as detailed in a review by CM. Marson, Tetrahedon 1992, 48:3660- 3720 and references therein.
- the compound of formula (VI) where R is H can be prepared from the compound of formula (IX) by hydrolysis in acidic solution, e.g. at pH 3 ⁇ 0.5, by adding a water miscible cosolvent, such as ethanol .
- the compound of formula (VI) where R is CHO can also be prepared by the hydrolysis of the compound of formula (IX) in the minimum of water, with the pH controlled as described above. Under these conditions the compound of formula (VI) where R is CHO precipitates as formed and can be filtered off.
- the compound of formula (IV) may be prepared by methods analogous to those described in Tetrahedron: Asymmetry Vol.4, p.1117 (1993) .
- Triethylamine (170ml) was added followed by N- (2-amino- 4, 6-dichloro-5-pyrimidinyl) formamide (W095/21161) (97g) .
- the suspension was heated under reflux -for about 17h to give a clear solution, which was cooled to 25 to 30°C and finely divided potassium carbonate (169g) was added.
- the suspension was stirred in this temperature range for about 0.5h then cooled to 0 to 5°C and the solids filtered off.
- the solids were washed with IMS (3 x 180ml and 1 x 140ml) and the combined filtrates and washings were concentrated under reduced pressure to a red gum. This was redissolved in IMS (1000ml) and the solution was concentrated under reduced pressure to a gum. The dilution and re-concentration were repeated twice more, and the final gum was redissolved in IMS (350ml) .
- the suspension was heated under reflux for about 4h and then cooled to about -5°C. After stirring at this temperature for about lh, the solids were filtered off and washed with IMS (2 x 100ml) . The combined filtrates and washings were concentrated under reduced pressure to a residual volume of about 400ml. This was redissolved in IMS (1000ml) and the solution was concentrated under reduced pressure to a gum. The dilution and re-concentration were repeated twice more, and the final gum was redissolved in IMS (350ml) . Meanwhile, triethylorthoformate (900ml) was cooled to 0 to 5°C and concentrated hydrochloric acid (80ml) was added, maintaining the temperature between 0 and 10°C.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (24)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE69818084T DE69818084T2 (en) | 1997-10-14 | 1998-10-14 | METHOD FOR PRODUCING CHLOROPURINE INTERMEDIATE PRODUCTS |
AU95476/98A AU738462B2 (en) | 1997-10-14 | 1998-10-14 | Process for the synthesis of chloropurine intermediates |
US09/529,385 US6646125B1 (en) | 1997-10-14 | 1998-10-14 | Process for the synthesis of chloropurine intermediates |
JP2000515898A JP4531250B2 (en) | 1997-10-14 | 1998-10-14 | Synthetic method of chloropurine intermediate |
APAP/P/2000/001790A AP1182A (en) | 1997-10-14 | 1998-10-14 | Proces for the synthesis of chloropurine intermediates. |
HU0003984A HUP0003984A3 (en) | 1997-10-14 | 1998-10-14 | Process for synthesis of carbocyclyc chloropurine nucleoside analogues |
KR1020007003921A KR100543845B1 (en) | 1997-10-14 | 1998-10-14 | Process for the Synthesis of Chloropurine Intermediates |
SI9830556T SI1023292T1 (en) | 1997-10-14 | 1998-10-14 | Process for the synthesis of chloropurine intermediates |
NZ503679A NZ503679A (en) | 1997-10-14 | 1998-10-14 | Preparation of (lB,4R)-cis-4- [2-amino-6-chloro-9R-purin- 9-yl] -2-cyclopentene-1-methanol hydrochloride salt. |
UA2000031789A UA54550C2 (en) | 1997-10-14 | 1998-10-14 | a process FOR CHLORPURINE INTERMEDIATES SYNTHESIS |
AT98949093T ATE249461T1 (en) | 1997-10-14 | 1998-10-14 | METHOD FOR PRODUCING CHLOROPURINE INTERMEDIATE PRODUCTS |
IL13532398A IL135323A (en) | 1997-10-14 | 1998-10-14 | Process for the synthesis of 4-[2-amino-6-chloro-9h-purine-9-yl]-2-cyclopentene-1-methanol |
SK536-2000A SK285331B6 (en) | 1997-10-14 | 1998-10-14 | Process for the synthesis of chloropurine intermediates |
PL98339904A PL188477B1 (en) | 1997-10-14 | 1998-10-14 | Method of synthesising intermediate chloropurin compounds |
CA002306958A CA2306958C (en) | 1997-10-14 | 1998-10-14 | Process for the synthesis of chloropurine intermediates |
BRPI9813048-0A BR9813048B1 (en) | 1997-10-14 | 1998-10-14 | process for the preparation of a compound. |
EA200000318A EA003183B1 (en) | 1997-10-14 | 1998-10-14 | Process for the synthesis of chloropurine intermediates |
EP98949093A EP1023292B1 (en) | 1997-10-14 | 1998-10-14 | Process for the synthesis of chloropurine intermediates |
DK98949093T DK1023292T3 (en) | 1997-10-14 | 1998-10-14 | Process for the synthesis of chlorpurin intermediates |
EEP200000162A EE04059B1 (en) | 1997-10-14 | 1998-10-14 | Method for the synthesis of chloropurine intermediates |
IS5423A IS2195B (en) | 1997-10-14 | 2000-03-28 | Method of synthesis of chloropurine intermediates |
NO20001896A NO325030B1 (en) | 1997-10-14 | 2000-04-12 | Process for the preparation of chlorpurine intermediates |
HR980147A HRP20000216B1 (en) | 1997-10-14 | 2000-04-14 | Process for the synthesis of chloropurine intermediates |
HK00106983A HK1027807A1 (en) | 1997-10-14 | 2000-11-02 | Process for the synthesis of chloropurine intermediates |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9721780.6 | 1997-10-14 | ||
GBGB9721780.6A GB9721780D0 (en) | 1997-10-14 | 1997-10-14 | Process for the synthesis of chloropurine intermediates |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999019327A1 true WO1999019327A1 (en) | 1999-04-22 |
Family
ID=10820547
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1998/003080 WO1999019327A1 (en) | 1997-10-14 | 1998-10-14 | Process for the synthesis of chloropurine intermediates |
Country Status (44)
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6448402B2 (en) * | 1997-11-27 | 2002-09-10 | Lonza Ag | Process for the preparation of aminoalcohol derivatives and their further conversion to (1R, 4S)-4-((2-amino-6-chloro-5-formamido-4-pyrimidinyl)-amino)-2-cyclopentenyl-1-methanol |
FR2849030A1 (en) * | 2002-12-20 | 2004-06-25 | Isochem Sa | Pure N-(2-amino-4,6-dihalo-pyrimidin-6-yl)-formamide production, for use as intermediate for nucleotide antiviral agents, from corresponding diamine, formic acid and acetic anhydride |
US7557209B2 (en) | 2003-09-04 | 2009-07-07 | Glaxo Group Limited | Process for the preparation of (1S,4R)-cis-4-[2-amino-6-chloro-9H-purin-9-yl]-2-cyclopentene-1-methanol |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100465174C (en) * | 2006-06-13 | 2009-03-04 | 中国科学院上海有机化学研究所 | Process for preparing optics pure abacavir |
KR101109476B1 (en) * | 2009-06-26 | 2012-01-31 | 현대제철 주식회사 | Jig device for changing cylinder |
MX356891B (en) | 2010-01-27 | 2018-06-19 | Viiv Healthcare Co | Antiviral therapy. |
CN104672239A (en) * | 2013-11-26 | 2015-06-03 | 上海迪赛诺化学制药有限公司 | Process for preparing abacavir intermediate in formula V by adopting one-pot method |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2217320A (en) * | 1988-01-20 | 1989-10-25 | Univ Minnesota | Dideoxydidehydrocarbocyclic nucleosides |
EP0434450A2 (en) * | 1989-12-22 | 1991-06-26 | The Wellcome Foundation Limited | Therapeutic nucleosides |
WO1991015490A1 (en) * | 1990-04-06 | 1991-10-17 | Glaxo Inc. | Synthesis of purine substituted cyclopentene derivatives |
US5329008A (en) * | 1993-04-07 | 1994-07-12 | Glaxo Inc. | Synthesis of a 3,4-dihydroxy-1-cyclopentanylpurinone |
WO1995021161A1 (en) * | 1994-02-04 | 1995-08-10 | The Wellcome Foundation Limited | Chloropyrimide intermediates |
US5763607A (en) * | 1988-01-20 | 1998-06-09 | Regents Of The University Of Minnesota | Preparation of optically-active isomers of dideoxycarbocyclic nucleosides |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4268672A (en) * | 1977-02-09 | 1981-05-19 | The Regents Of The University Of Minnesota | Adenosine deaminase resistant antiviral purine nucleosides and method of preparation |
JPS6175A (en) * | 1984-03-06 | 1986-01-06 | ブリストル−マイア−ズ コムパニ− | Antipsychotic 1-fluorophenylbutyl-4-(2-pyrimidinyl) piperazine derivative |
NZ229453A (en) * | 1988-06-10 | 1991-08-27 | Univ Minnesota & Southern Rese | A pharmaceutical composition containing purine derivatives with nucleosides such as azt, as antiviral agents |
GB8815265D0 (en) * | 1988-06-27 | 1988-08-03 | Wellcome Found | Therapeutic nucleosides |
SK285228B6 (en) * | 1997-05-13 | 2006-09-07 | Lonza Ag | Process for the preparation of a racemic or optically active 4-(hydroxymethyl)-2-cyclopentene derivative and racemic N-butyryl-1-amino-4-(hydroxymethyl)-2-cyclopentene |
-
1997
- 1997-10-14 GB GBGB9721780.6A patent/GB9721780D0/en not_active Ceased
-
1998
- 1998-10-12 PE PE1998000960A patent/PE121899A1/en not_active IP Right Cessation
- 1998-10-13 ZA ZA9809338A patent/ZA989338B/en unknown
- 1998-10-13 MA MA25292A patent/MA24676A1/en unknown
- 1998-10-13 MY MYPI98004673A patent/MY127470A/en unknown
- 1998-10-13 CO CO98059323A patent/CO4980899A1/en unknown
- 1998-10-13 EG EG124098A patent/EG21730A/en active
- 1998-10-13 AR ARP980105097A patent/AR014921A1/en active IP Right Grant
- 1998-10-13 IN IN1821CA1998 patent/IN184590B/en unknown
- 1998-10-14 RS YUP-202/00A patent/RS49710B/en unknown
- 1998-10-14 IL IL13532398A patent/IL135323A/en not_active IP Right Cessation
- 1998-10-14 EA EA200000318A patent/EA003183B1/en not_active IP Right Cessation
- 1998-10-14 JP JP2000515898A patent/JP4531250B2/en not_active Expired - Lifetime
- 1998-10-14 AT AT98949093T patent/ATE249461T1/en active
- 1998-10-14 NZ NZ503679A patent/NZ503679A/en not_active IP Right Cessation
- 1998-10-14 PL PL98339904A patent/PL188477B1/en unknown
- 1998-10-14 ID IDW20000707A patent/ID24927A/en unknown
- 1998-10-14 AU AU95476/98A patent/AU738462B2/en not_active Expired
- 1998-10-14 CA CA002306958A patent/CA2306958C/en not_active Expired - Lifetime
- 1998-10-14 GE GEAP19985300A patent/GEP20022679B/en unknown
- 1998-10-14 TW TW087117057A patent/TW436488B/en not_active IP Right Cessation
- 1998-10-14 SK SK536-2000A patent/SK285331B6/en not_active IP Right Cessation
- 1998-10-14 EE EEP200000162A patent/EE04059B1/en unknown
- 1998-10-14 DE DE69818084T patent/DE69818084T2/en not_active Expired - Lifetime
- 1998-10-14 PT PT98949093T patent/PT1023292E/en unknown
- 1998-10-14 WO PCT/GB1998/003080 patent/WO1999019327A1/en active IP Right Grant
- 1998-10-14 US US09/529,385 patent/US6646125B1/en not_active Expired - Lifetime
- 1998-10-14 HU HU0003984A patent/HUP0003984A3/en unknown
- 1998-10-14 UA UA2000031789A patent/UA54550C2/en unknown
- 1998-10-14 ES ES98949093T patent/ES2205553T3/en not_active Expired - Lifetime
- 1998-10-14 CZ CZ20001367A patent/CZ294482B6/en not_active IP Right Cessation
- 1998-10-14 AP APAP/P/2000/001790A patent/AP1182A/en active
- 1998-10-14 CN CNB988121522A patent/CN1160354C/en not_active Expired - Lifetime
- 1998-10-14 TR TR2000/00976T patent/TR200000976T2/en unknown
- 1998-10-14 DK DK98949093T patent/DK1023292T3/en active
- 1998-10-14 EP EP98949093A patent/EP1023292B1/en not_active Expired - Lifetime
- 1998-10-14 BR BRPI9813048-0A patent/BR9813048B1/en not_active IP Right Cessation
- 1998-10-14 KR KR1020007003921A patent/KR100543845B1/en not_active IP Right Cessation
-
2000
- 2000-03-28 IS IS5423A patent/IS2195B/en unknown
- 2000-04-07 OA OA1200000101A patent/OA11370A/en unknown
- 2000-04-12 NO NO20001896A patent/NO325030B1/en not_active IP Right Cessation
- 2000-04-14 HR HR980147A patent/HRP20000216B1/en not_active IP Right Cessation
- 2000-04-18 BG BG104352A patent/BG64597B1/en unknown
- 2000-11-02 HK HK00106983A patent/HK1027807A1/en not_active IP Right Cessation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2217320A (en) * | 1988-01-20 | 1989-10-25 | Univ Minnesota | Dideoxydidehydrocarbocyclic nucleosides |
US5763607A (en) * | 1988-01-20 | 1998-06-09 | Regents Of The University Of Minnesota | Preparation of optically-active isomers of dideoxycarbocyclic nucleosides |
EP0434450A2 (en) * | 1989-12-22 | 1991-06-26 | The Wellcome Foundation Limited | Therapeutic nucleosides |
WO1991015490A1 (en) * | 1990-04-06 | 1991-10-17 | Glaxo Inc. | Synthesis of purine substituted cyclopentene derivatives |
US5329008A (en) * | 1993-04-07 | 1994-07-12 | Glaxo Inc. | Synthesis of a 3,4-dihydroxy-1-cyclopentanylpurinone |
WO1995021161A1 (en) * | 1994-02-04 | 1995-08-10 | The Wellcome Foundation Limited | Chloropyrimide intermediates |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6448402B2 (en) * | 1997-11-27 | 2002-09-10 | Lonza Ag | Process for the preparation of aminoalcohol derivatives and their further conversion to (1R, 4S)-4-((2-amino-6-chloro-5-formamido-4-pyrimidinyl)-amino)-2-cyclopentenyl-1-methanol |
EP1418170A2 (en) * | 1997-11-27 | 2004-05-12 | Lonza AG | Process for the preparation of optically active amino alcohols by optical resolution |
EP1418170A3 (en) * | 1997-11-27 | 2004-05-19 | Lonza AG | Process for the preparation of optically active amino alcohols by optical resolution |
EP1508565A1 (en) * | 1997-11-27 | 2005-02-23 | Lonza AG | Process for the preparation of optically active aminoalcohols |
US7229981B2 (en) | 1997-11-27 | 2007-06-12 | Lonza Ag | Process for the preparation of aminoalcohol derivatives and their further conversion to (1R,4S)-4-(2-amino-6-chloro-5-formamido-4-pyrimidinyl)-amino)-2-cyclopentenyl-1-methanol |
US7338945B2 (en) | 1997-11-27 | 2008-03-04 | Lonza Ag | Process for the preparation of aminoalcohol derivatives and their further conversion to (1R, 4S)-4(2-amino-6-chloro-5-formamido-4-pyrimidinyl)-amino-2-cyclopentenyl-1-methanol |
US7358073B2 (en) | 1997-11-27 | 2008-04-15 | Lonza Ag | Process for the preparation of aminoalcohol derivatives and their further conversion to (1R, 4S)-4(2-amino-6-chloro-5-formamido-4- pyrimidinyl)-amino-2-cyclopentenyl-1-methanol |
FR2849030A1 (en) * | 2002-12-20 | 2004-06-25 | Isochem Sa | Pure N-(2-amino-4,6-dihalo-pyrimidin-6-yl)-formamide production, for use as intermediate for nucleotide antiviral agents, from corresponding diamine, formic acid and acetic anhydride |
US7557209B2 (en) | 2003-09-04 | 2009-07-07 | Glaxo Group Limited | Process for the preparation of (1S,4R)-cis-4-[2-amino-6-chloro-9H-purin-9-yl]-2-cyclopentene-1-methanol |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3670012B2 (en) | Chloropyrimidine intermediate | |
JP2002525374A (en) | Antiviral purine derivatives | |
EP1023292B1 (en) | Process for the synthesis of chloropurine intermediates | |
US8097723B2 (en) | Process for the preparation of abacavir | |
KR100491941B1 (en) | Process for preparing purine derivatives | |
MXPA00003379A (en) | Process for the synthesis of chloropurine intermediates | |
US20230357181A1 (en) | Methods and compounds useful in the sythesis of an aak1 inhibitor | |
TWI588146B (en) | Synthetic method of entecavir and intermediate compounds thereof | |
WO2005058926A1 (en) | New process for preparing diisopropyl ((1-((2-amino-6-chloro-9h-purin-9-yl)methyl)cyclopropyl)oxy)methylphosphonate | |
JPH11209364A (en) | Gamma-alkoxycarboxylic acid derivative and its production | |
WO2012138954A1 (en) | Forms of cidofovir |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 135323 Country of ref document: IL Ref document number: P-202/00 Country of ref document: YU Ref document number: 98812152.2 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 95476/98 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 503679 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2000/003379 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 5362000 Country of ref document: SK |
|
ENP | Entry into the national phase |
Ref document number: 2306958 Country of ref document: CA Ref document number: 2306958 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020007003921 Country of ref document: KR Ref document number: 2000/00976 Country of ref document: TR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998949093 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2000-1367 Country of ref document: CZ Ref document number: P20000216A Country of ref document: HR Ref document number: 200000318 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09529385 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1998949093 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: PV2000-1367 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1020007003921 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 95476/98 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1998949093 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: PV2000-1367 Country of ref document: CZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 1020007003921 Country of ref document: KR |